

correlation to be calculated. None of the other parameters returned abnormal findings except a mild white cell elevation. All six troponins measured were negative. The only urine toxicology screen performed was positive for benzodiazepines only and was in a patient whose history was strongly convincing for heavy mephedrone usage.

## DISCUSSION

This case series forms the largest such report describing mephedrone toxicity to date. The findings support those previously reported in individual case studies and also validate predictions of a psychoactive and cardiovascular toxicity pattern, similar to amphetamine and cocaine, as the likely presentation with mephedrone in overdose or regular usage.<sup>2 4 5 9</sup> The predominance of anxiety, chest discomfort and paraesthesia, with a not insignificant rate of collapse, seizures and confusion all contribute to a high admission rate (51%).

It is noted that during the study period presentations related to other drugs of abuse were relatively small, only 31% of the number of mephedrone attendances even when cocaine, cannabis and heroin are combined together. This may be due to the severity of symptoms but it may also reflect the drug's usage by a naive population. Its ready availability as a 'legal high' appeared to result in its usage by groups without experience of recreational substances. They may have been unprepared for symptoms and, tallied with its 'legal' status, have been more willing to admit to its usage and seek help.

Our findings point to a pattern of addiction for this drug with patients reporting an inability to abstain after regular use.<sup>10</sup> In addition, users describe bingeing until exhausting supplies or the severity of symptoms forced them to seek medical attention.<sup>11</sup>

Although this work helps define the syndrome of mephedrone toxicity, we recognise that our qualification for subject inclusion was purely historical and lacked a formal objective test. We believe further study would be of benefit in defining the pathological effects of this drug in overdose. Any future study would ideally also contain provision for urine<sup>6 12 13</sup> or plasma testing both to qualify inclusion and quantify levels in subjects enrolled.

This may then guide discharge decisions and help define observation periods and potential treatment protocols.

**Competing interests** None declared.

**Contributors** LR, study design, data collection and analysis; CM, data collection; MM, study design, editing.

**Provenance and peer review** Not commissioned; externally peer reviewed.

## REFERENCES

1. **Camilleri A**, Johnston MR, Brennan M, *et al*. Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine,  $\alpha$ -phthalimidopropiophenone and *N*-ethylcathinone. *Forensic Sci Int* 2010;**197**:59–66.
2. **Gustavsson D**, Escher C. Mefedron — Internetdrog som tycks ha kommit för att stanna (Mephedrone—Internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substance) [in Swedish]. *Lakartidningen* 2009;**106**:2769–71.
3. **Morris K**. UK places generic ban on mephedrone drug family. *Lancet* 2010;**375**:1333–4.
4. **Wood DM**, Davies S, Puchnarewicz M, *et al*. Recreational use of 4-methylmethcathinone (4-MMC) presenting with sympathomimetic toxicity and confirmed by toxicological screening [abstract]. In: Abstracts of the 2009 North American Congress of Clinical Toxicology annual meeting, September 21–26, 2009, San Antonio, Texas, USA. *Clin Toxicol* 2009;**47**:733.
5. **Dickson AJ**, Vorce SP, Levine B, *et al*. Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. *J Anal Toxicol* 2010;**34**:162–8.
6. **Sammler EM**, Foley PL, Lauder GD, *et al*. A harmless high? *Lancet* 2010;**376**:742.
7. **Newcombe R**. *Mephedrone: use of mephedrone (M-cat, Meow) in Middlesbrough*. Manchester, UK: Lifeline Publications, 2009.
8. **Home Office**. ACMD report on the consideration of the cathinones. <http://drugs.homeoffice.gov.uk/publication-search/acmd/acmd-cathinodes-report-2010> Posted 31 March 2010. (accessed 15 April 2010).
9. **Measham F**, Moore K, Newcombe R, *et al*. Tweaking, bombing, dabbing, and stockpiling: the emergence of mephedrone and the perversity of prohibition. *Drugs and Alcohol Today* 2010;**10**:14–21.
10. **Winstock AR**, Marsden J, Mitchelson L. What should be done about mephedrone? *BMJ* 2010;**340**:c1605.
11. **Psychonaut Web Mapping Research Group**. *Mephedrone report*. Institute of Psychiatry, London, UK: King's College London, 2009.
12. **Meyer M**, Peters F, Maurer H. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography–mass spectrometry. *Annales de Toxicologie Analytique* 2009;**21**(Suppl 1):20.
13. **Torrance H**, Cooper G. The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. *Forensic Sci Int* 2010;**202**:e62–3.

## Correction

Towards evidence based emergency medicine: PRIVATE Best BETs from the Manchester Royal Infirmary. Craig Ferguson *Emerg Med J* 2011;**28**:990. The correct title should have been published as: Towards evidence based emergency medicine: Best BETs from the Manchester Royal Infirmary. Apologises for any inconvenience caused.

*Emerg Med J* 2011;**28**:1058. doi:10.1136/emered-2011-200720corr1